Improved GPCR ligands from nanobody tethering

• Published in: Nature communications 2020-04, Vol.11 (1), p.2087-2087, Article 2087
• Main Authors: Cheloha, Ross W., Fischer, Fabian A., Woodham, Andrew W., Daley, Eileen, Suminski, Naomi, Gardella, Thomas J., Ploegh, Hidde L.
• Format: Article
• Language: English
• Subjects: 631/92/436/2387; 631/92/552; 631/92/611; 96; 96/1; 96/106; Amino Acid Sequence; Animals; Antibodies; Bioactive compounds; Biological activity; Conjugates; Conjugation; Female; G protein-coupled receptors; HEK293 Cells; Humanities and Social Sciences; Humans; Immunoglobulins; Ligands; Membrane proteins; Mice; Models, Molecular; multidisciplinary; Nanobodies; Parathyroid; Parathyroid hormone; Parathyroid Hormone - metabolism; Peptides; Peptides - chemistry; Peptides - metabolism; Protein Binding; Proteins; Receptor, Parathyroid Hormone, Type 1 - metabolism; Receptors; Receptors, G-Protein-Coupled - metabolism; Science; Science (multidisciplinary); Selectivity; Single-Domain Antibodies - metabolism; Tethering
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-020-15884-8

Antibodies conjugated to bioactive compounds allow targeted delivery of therapeutics to cell types of choice based on that antibody’s specificity. Here we develop a new type of conjugate that consists of a nanobody and a peptidic ligand for a G protein-coupled receptor (GPCR), fused via their C-termini. We address activation of parathyroid hormone receptor-1 (PTHR1) and improve the signaling activity and specificity of otherwise poorly active N-terminal peptide fragments of PTH by conjugating them to nanobodies (VHHs) that recognize PTHR1. These C-to-C conjugates show biological activity superior to that of the parent fragment peptide in vitro. In an exploratory experiment in mice, a VHH-PTH peptide conjugate showed biological activity, whereas the corresponding free peptide did not. The lead conjugate also possesses selectivity for PTHR1 superior to that of PTH(1-34). This design approach, dubbed “conjugation of ligands and antibodies for membrane proteins” (CLAMP), can yield ligands with high potency and specificity. Antibodies conjugated to bioactive compounds can allow targeted delivery of therapeutics. Here the authors present a strategy for fusing nanobodies to suboptimal GPCR peptide ligands to potently and selectively activate receptors.